Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

Expert Opinion on Investigational Drugs

Volumn 15, Issue 8, 2006, Pages 873-886

  Van der Schyf, Cornelis J ^a   Gal, Shunit ^b   Geldenhuys, Werner J ^a   Youdim, Moussa B H ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Adenosine A2A antagonists; Alzheimer's disease; Amyotrophic lateral sclerosis; Ca2+ channel blockers; Choline acetylcholinesterase inhibitors; Iron chelators; Monoamine oxidase inhibitors; Multifunctional drugs; Neurodegenerative diseases; Neuroprotection; NMDA receptor antagonists; Parkinson's disease; Stroke

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2 RECEPTOR ANTAGONIST; AMINE OXIDASE (FLAVIN CONTAINING); CAFFEINE; CHOLINESTERASE INHIBITOR; DEFEROXAMINE; DIZOCILPINE; DONEPEZIL; EPIGALLOCATECHIN GALLATE; FLUOXETINE; GALANTAMINE; GLUTAMATE RECEPTOR ANTAGONIST; IRON CHELATING AGENT; ISTRADEFYLLINE; JWS USC 75IX; LADOSTIGIL; LAZABEMIDE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFIRACETAM; NEUROPROTECTIVE AGENT; PLACEBO; RANITIDINE DERIVATIVE; RASAGILINE; RIVASTIGMINE; RS 1259; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; APOPTOSIS; CHOLINERGIC ACTIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; DEGENERATIVE DISEASE; DEPRESSION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IRON CHELATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ACETYLCHOLINE; ANIMALS; APOPTOSIS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CARBAMATES; CHOLINESTERASE INHIBITORS; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; FREE RADICAL SCAVENGERS; HUMANS; HYDROXYQUINOLINES; IRON CHELATING AGENTS; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PIPERAZINES; PURINES; RECEPTOR, ADENOSINE A2A; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 33746840955     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.8.873     Document Type: Review

References (108)

1. ROTH BL, SHEFFLER DJ, KROEZE WK: Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. (2004) 3:353-359.
2. MORPHY R, KAY C, RANKOVIC Z: From magic bullets to designed multiple ligands. Drug Discov. Today (2004) 9:641-651.
3. SCHMITT B, BERNHARDT T, MOELLER HJ, HEUSER I, FROLICH L: Combination therapy in Alzheimer's disease: a review of current evidence. CNS Drugs (2004) 18:827-844.
4. MORPHY R, RANKOVIC Z: Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. (2005) 48:6523-6543.
5. RUTHERFORD GW, SANGANI PR, KENNEDY GE: Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst. Rev. (2003) 4:CD002037.
6. 2-adrenoceptor agonists and corticosteroids for asthma. Treat. Respir. Med. (2004) 3:279-289.
7. FRISHMAN WH, ZUCKERMAN AL: Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. (2004) 2:675-781.
8. ZERKAK D, DOUGADOS M: Benefit/risk of combination therapies. Clin. Exp. Rheumatol. (2004) 35(Suppl. 5):S71-S76.
9. KEITH CT, BORISY AA, STOCKWELL BR: Multicomponent therapeutics for networked systems. Nat. Rev. Drug. Discov. (2005) 4:71-78.
10. SMID P, COOLEN HK, KEIZER HG et al.: Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[ω-(1H-indol-3-yl)alkyl] piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition. J. Med. Chem. (2005) 48:6855-6869.
11. GURWITZ JH: Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch. Intern. Med. (2004) 164:1957-1959.
12. YOUDIM MBH, BUCCAFUSCO JJ: CNS targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. J. Neural. Transm. (2005) 112:519-537.
13. YOUDIM MBH, BUCCAFUSCO JJ: Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. (2005) 26:27-35.
14. CHRISTIAANS JAM, TIMMERMAN H: Cardiovascular hybrid drugs: combination of more than one pharmacological property in one single molecule. Eur. J. Pharm. Sci. (1996) 4:1-22.
15. CSERMELY P, AGOSTON V, PONGOR S: The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. (2005) 26:178-182.
16. YOUDIM MBH, FRIDKIN M, ZHENG H: Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech. Ageing Dev. (2005) 126:317-326.
17. ZHENG H, WEINER LM, BAR-AM O et al.: Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. (2005) 13:773-783.
18. AKK G, STEINBACH JH: Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site. J. Neurosci. (2005) 25:1992-2001.
19. DENGIZ AN, KERSHAW P: The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. CNS Spectr. (2004) 9:377-392.
20. GREENBLATT HM, KRYGER G, LEWIS T, SILMAN I, SUSSMAN JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. (1999) 463:321-326.
21. 2+ signals and neurotransmitter release. Mol. Pharmacol. (2003) 64:1217-1226.
22. FRANCIS PT, PALMER AM, SNAPE M, WILCOCK GK: The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry (1999) 66:137-147.
23. NARAHASHI T, MORIGUCHI S, ZHAO X, MARSZALEC W, YEH JZ: Mechanisms of action of cognitive enhancers on neuroreceptors. Biol. Pharm. Bull. (2004) 27:1701-1706.
24. MORIGUCHI S, MARSZALEC W, ZHAO X, YEH JZ, NARAHASHI T: Potentiation of N-methyl-D-aspartate-induced currents by the nootropic drug nefiracetam in rat cortical neurons. J. Pharmacol. Exp. Ther. (2003) 307:160-167.
25. WILKINSON D, MURRAY J: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int. J. Geriatr. Psychiatry (2001) 16:852-857.
26. SNAPE MF, MISRA A, MURRAY TK, DE SOUZA RJ, WILLIAMS JL, CROSS AJ, GREEN AR: A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacol. (1999) 38:181-193.
27. 3H]MK-801 binding in rat cerebral cortex. Neurosci. Lett. (1999) 272:21-24.
28. OYAIZU M, NARAHASHI T: Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam. Brain Res. (1999) 822:72-79.
29. NISHIZAKI T, MATSUOKA T, NOMURA T et al.: Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. Alzheimer Dis. Assoc. Disord. (2000) 14(Suppl. 1):S82-S94.
30. NISHIZAKI T, MATSUOKA T, NOMURA T et al.: Nefiracetam modulates acetylcholine receptor currents via two different signal transduction pathways. Mol. Pharmacol. (1998) 53:1-5.
31. KEMP JA, McKERNAN RM: NMDA receptor pathways as drug targets. Nat. Neurosci. (2002) 5:1039-1042 (Supplement).
32. ZHAO X, YEH JZ, NARAHASHI T: Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors. Ann. NY Acad. Sci. (2001) 939:179-186.
33. TODA N, TAGO K, MARUMOTO S et al.: A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg. Med. Chem. (2003) 11:4389-4415.
34. McKENNA MT, PROCOTOR GR, YOUNG LC, HARVEY AL: Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J. Med. Chem. (1997) 40:3516-3523.
35. ABE Y, AOYAGI A, HARA T et al.: Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J. Pharmacol. Sci. (2003) 93:95-105.
36. SAGI Y, WEINSTOCK M, YOUDIM MBH: Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem. (2003) 86:290-297.
37. TERRY AV, GATTU M, BUCCAFUSCO JJ, SOWELL JW, KOSH JW: Ranitidine JWS-USC-75IX, enhances memory-related tasks performance in rats. Drug Develop. Res. (1999) 42:97-106.
38. 2+ channels and nicotinic receptors. Bioorg. Med. Chem. (2004) 12:2199-2218.
39. OROZCO C, DE LOS RIOS C, ARIAS E et al.: ITH4012 (ethyl-5-amino-6,7,8,9 -tetrahydro-2-methyl-4- phenylbenzol[1,8]naphthyridine-3-carboxylate), a novel acetylcholinesterase inhibitor with 'calcium promotor' and neuroprotective properties. J. Pharmacol. Exp. Ther. (2004) 310:987-994.
40. COLLINS F, LILE JD: The role of dihydropyridine-sensitive voltage-gated calcium channels in potassium-mediated neuronal survival. Brain Res. (1989) 502:99-108.
41. ZECCA L, YOUDIM MB, RIEDERER P, CONNOR JR, CRICHTON RR: Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. (2004) 5:863-873.
42. PANTOPOULOS K: Iron metabolism and the IRE/IRP regulatory system: an update. Ann. NY Acad. Sci. (2004) 1012:1-13.
43. EISENSTEIN RS: Iron regulatory proteins and the molecular control of mammalian iron metabolism. Ann. Rev. Nutr. (2000) 20:627-662.
44. CRICHTON RR, WILMET S, LEGSSYER R, WARD RJ: Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells.J. Inorg. Biochem. (2002) 91:9-18.
45. ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 43:1609-1611.
46. ROGERS JT, LAHIRI DK: Metal and inflammatory targets for Alzheimer's disease. Curr. Drug Targets (2004) 5:535-551.
47. ROGERS JT, RANDALL JD, CAHILL CM et al.: An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. (2002) 277:45518-45528.
48. +-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. (2004) 279:15240-15247.
49. HILDITCH-MAGUIRE P, TRETTEL F, PASSANI LA, AUERBACH A, PERSICHETTI F, MacDONALD ME: Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. (2000) 9:2789-2797.
50. MANDEL S, MAOR G, YOUDIM MBH: Iron and α-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J. Mol. Neurosci. (2004) 24:401-416.
51. YOUDIM MBH, STEPHENSON G, BEN SHACHAR D: Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators; a lesson from 6-hydroxydopamine and iron chelators desferal and VK-28. Ann. NY Acad. Sci. (2004) 1012:306-325.
52. TEMLETT JA, LANDSBERG JP, WATT F, GRIME GW: Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. (1994) 62:134-146.
53. OESTREICHER E, SENGSTOCK GJ, RIEDERER P, OLANOW CW, DUNN AJ, ARENDASH GW: Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. (1994) 660:8-18.
54. GRUNBLATT E, MANDEL S, BERKUZKI T, YOUDIM MBH: Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. (1999) 14:612-618.
55. JAKOWEC MW, PETZINGER GM: 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. (2004) 54:497-513.
56. CUNNINGHAM MJ, NATHAN DG: New developments in iron chelators. Curr. Opin. Hematol. (2005) 12:129-134.
57. BEN-SHACHAR D, ESHEL G, RIEDERER P, YOUDIM MBH: Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Annal. Neurol. (1992) 32:S105-S110 (Supplement).
58. BEN-SHACHAR D, KAHANA N, KAMPEL V, WARSHAWSKY A, YOUDIM MBH: Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacol. (2004) 46:254-263.
59. KAUR DF, YANTIRI F, RAJAGOPALAN S et al.: Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 37:899-909.
60. ZHENG H, GAL S, WEINER LM et al.: Novel multifunctional neuroprotective iron chelator-monoamine oxidase drugs for neurodegenerative diseases; I. in vitro studies on iron chelation, antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. (2005) 95:68-78.
61. GAL S, ZHENG H, FRIDKIN M, YOUDIM MBH: Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases, II; in vivo selective brain monoamine oxidase inhibition and prevention of MPTP induced striatal dopamine depletion. J. Neurochem. (2005) 95:79-88.
62. AVRAMOVICH-TIROSH Y, AMIT T, ZHENG H, FRIDKIN M, YOUDIM MBH: Neurorescue and reduction of amyloid-β peptide by novel multi-functional brain permeable iron-chelators. J. Neurosci. (2006) (Submitted).
63. STERLING J, HERZIG Y, GOREN T et al.: Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. (2002) 45:5260-5279.
64. RIEDERER P, DANIELCZYK W, GRUNBLATT E: Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicol. (2004) 25:271-277.
65. SRAMEK JJ, CUTLER NR: Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging (1999) 14:359-373.
66. YOUDIM MBH, BAR AM O, YOGEV-FALACH M et al.: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. (2005) 79:172-179.
67. MAIA L, DE MENDONCA A: Does caffeine intake protect from Alzheimer's disease? Eur. J. Neurol. (2002) 9:377-382.
68. DALL'IGNA OP, SOUZA DO, LARA DR: Caffeine as a neuroprotective adenosine receptor antagonist. Ann. Pharmacother. (2004) 38:717-718.
69. 2A receptors. Neurobiol. Aging (2005) 26:957-964.
70. 2A receptor blockade of β-amyloid neurotoxicity. Br. J. Pharmacol. (2003) 138:1207-1209.
71. 2A receptor antagonists. Bioorg. Med. Chem. (2003) 11:1299-1310.
72. 2A receptor antagonism. J. Biol. Chem. (2002) 277:36040-36044.
73. 2A receptor antagonists. Neurology (2003) 61(11 Suppl. 6):S62-S68.
74. HORN J, DE HAAN RJ, VERMEULEN M, LUITEN PG, LIMBURG M: Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke (2001) 32:2433-2438.
75. OVBIAGELE B, KIDWELL CS, STARKMAN S, SAVER JL: Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr. Treat. Options Cardiovasc. Med. (2003) 5:441-449.
76. LIPTON P: Ischemic cell death in brain neurons. Physiol. Rev. (1999) 79:1431-1568.
77. FLODEN AM, LI S, COMBS CK: β-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor α and NMDA receptors. J. Neurosci. (2005) 25:2566-2575.
78. ZOU JY, CREWS FT: TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition. Brain Res. (2005) 1034:11-24.
79. VAN KOOTEN F, KOUDSTAAL PJ: Epidemiology of post-stroke dementia. Haemostasis (1998) 28:124-133.
80. KALARIA RN, BALLARD C: Stroke and cognition. Curr. Atheroscler. Rep. (2001) 3:334-339.
81. ARUNDINE M, TYMIANSKI M: Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. (2004) 61:657-68.
82. GREEN RA, ODERGREN T, ASHWOOD T: Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol. Sci. (2003) 24:402-408.
83. GORUGLU A, KINS T, COBANOGLU S, UNAL F, IZGI NI, YANIK B, KUCUK M: Reduction of edema and infarction by memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir. (Wien.) (2000) 142:1287-1292.
84. GERRIETS T, STOLZ E, WALBERER M, KAPS M, BACHMANN G, FISHER M: Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance. Stroke (2003) 34:2234-2239.
85. RAMI A, KRIEGLSTEIN J: Neuronal protective effects of calcium antagonists in cerebral ischemia. Life Sci. (1994) 55:2105-2113.
86. SASAKI T, EGUCHI S, KIRIYAMA T: A facial synthesis of mono-oxa and aza-cage compounds via transanullar cyclizations. Tet. Lett. (1971):2651-2654.
87. 5,9] undecan-3,6-dione system. Tetrahedron (1974) 30:2707-2712.
88. VAN DER SCHYF CJ, SQUIER GJ, COETZEE WA: Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. Pharmacol. Res. Commun. (1986) 18:407-417.
89. REISBERG B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ: Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. (2003) 348:1333-1341.
90. JAIN KK: Evaluation of memantine for neuroprotection in dementia. Expert. Opin. Investig. Drugs (2000) 9:1397-1406.
91. FARLOW MR: NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics (2004) 59:22-27.
92. VEDANTAM S: FDA OKs drug to treat advanced Alzheimer's. Washington Post Saturday (18 October 2003).
93. PARSONS CG, DANYSZ W, QUACK G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacol. (1999) 38:735-767.
94. KIEWERT C, HARTMANN J, STOLL J, THEKKUMKARA TJ, VAN DER SCHYF CJ, KLEIN J: NGP1-01 is a brain-permeable dual blocker of neuronal voltage- and ligand-operated calcium channels. Neurochem. Res. (2006) 31:395-399.
95. GELDENHUYS WJ, MALAN SF, BLOOMQUIST JR, MARCHAND AP, VAN DER SCHYF CJ: Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med. Res. Rev. (2005) 25:21-48.
96. KADABA PK: Rational drug design and the discovery of the Δ-2-1,2,3-triazolines, a unique class of anticonvulsant and antiischemic agents. Curr. Med. Chem. (2003) 10:2081-2108.
97. NAN F, BZDEGA T, PSHENICHKIN S, WROBLEWSKI JT, WROBLEWSKA B, NEALE JH, KOZIKOWSKI AP: Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J. Med. Chem. (2000) 43:772-77.
98. NICOLETTI F, BRUNO V, COPANI A, CASABONA, G: KNOPFEL T: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. (1996) 19:267-271.
99. LEE ES, CHEN H, SOLIMAN KF, CHARLTON CG: Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology (2005) 26:361-371.
100. MULLER T, RENGER K, KUHN W: Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch. Neurol. (2004) 61:657-660.
101. MULLER T, VOSS B, HELLWIG K, PRZUNTEK H: Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. NeuroRehabilitation (2003) 18:271-275.
102. QUADRI P, FRAGIACOMO C, PEZZATI R et al.: Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer's disease, and vascular dementia. Am. J. Clin. Nutr. (2004) 80:114-122.
103. SACHDEV P: Homocysteine, cerebrovascular disease and brain atrophy. J. Neurol. Sci. (2004) 226:25-29
104. SMITH LA, JACKSON MJ, HANSARD MJ, MARATOS E, JENNER P: Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov. Disord. (2003) 18:487-495.
105. ZAPPIA M, CRESCIBENE L, ARABIA G et al.: Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin. Neuropharmacol. (2002) 25:79-82.
106. MULLER T, WOITALLA D, SAFT C, KUHN W: Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat. Disord. (2000) 6:171-173.
107. PRZUNTEK H, MULLER T, RIEDERER P: Diagnostic staging of Parkinson's disease: conceptual aspects. J. Neural Transm. (2004) 111:201-216.
108. RIEDERER P, GILLE G, MULLER T et al.: Practical importance of neuroprotection in Parkinson's disease. J. Neurol. (2002) 249(Suppl. 3):III/53-III/56.